● Recruiting

Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients

Condition: Bone Sarcoma · Osteosarcoma · Sponsor: Centre Leon Berard

PhasePhase 2

Planned participants36

Who can joinAll sexes, 12 Years to no upper limit

Healthy volunteersNo

About this study

This is a multicenter phase II study concerning patients with high-grade bone sarcoma (HGBS) without complete remission after standard treatment at diagnosis or at relapse. Patients will be treated with regorafenib + best supportive care (BSC) for a maximum of 12 months as maintenance therapy after standard line therapy completion. Progression free rate (PFR) data will be collected and analysed for all included patients to evaluate if regorafenib + BSC can be considered as an interesting treatment for further investigations in this indication.

This description comes directly from the study's public registry record.

Talk to the study team

Julien GAUTIER · +33(0)426556829 · julien.gautier@lyon.unicancer.fr

Always discuss trial participation with your own doctor first.

Locations (16)

Chu Besancon	Besançon, France	Not Yet Recruiting
Institut Bergonie	Bordeaux, France	Recruiting
Centre Georges Francois Leclerc	Dijon, France	Not Yet Recruiting
Centre Oscar Lambret	Lille, France	Not Yet Recruiting
Centre Leon Berard	Lyon, France	Recruiting
Hopital de La Timone	Marseille, France	Recruiting
Icm Val D'Aurelle	Montpellier, France	Not Yet Recruiting
Hotel Dieu Nantes	Nantes, France	Not Yet Recruiting
Institut Curie	Paris, France	Recruiting
Hôpital COCHIN	Paris, France	Recruiting
Ico Rene Gauducheau	Saint-Herblain, France	Recruiting
Chu Saint-Etienne	Saint-Priest-en-Jarez, France	Not Yet Recruiting

+ 4 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04698785